Cargando…
Haprolid Inhibits Tumor Growth of Hepatocellular Carcinoma through Rb/E2F and Akt/mTOR Inhibition
Background: Hepatocellular carcinoma (HCC) represents a major health burden with limited curative treatment options. There is a substantial unmet need to develop innovative approaches to impact the progression of advanced HCC. Haprolid is a novel natural component isolated from myxobacteria. Haproli...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139901/ https://www.ncbi.nlm.nih.gov/pubmed/32155915 http://dx.doi.org/10.3390/cancers12030615 |
_version_ | 1783518872833359872 |
---|---|
author | Xing, Jun Bhuria, Vikas Bui, Khac Cuong Nguyen, Mai Ly Thi Hu, Zexi Hsieh, Chih-Jen Wittstein, Kathrin Stadler, Marc Wilkens, Ludwig Li, Jun Kalesse, Markus Bozko, Przemyslaw Plentz, Ruben R. |
author_facet | Xing, Jun Bhuria, Vikas Bui, Khac Cuong Nguyen, Mai Ly Thi Hu, Zexi Hsieh, Chih-Jen Wittstein, Kathrin Stadler, Marc Wilkens, Ludwig Li, Jun Kalesse, Markus Bozko, Przemyslaw Plentz, Ruben R. |
author_sort | Xing, Jun |
collection | PubMed |
description | Background: Hepatocellular carcinoma (HCC) represents a major health burden with limited curative treatment options. There is a substantial unmet need to develop innovative approaches to impact the progression of advanced HCC. Haprolid is a novel natural component isolated from myxobacteria. Haprolid has been reported as a potent selective cytotoxin against a panel of tumor cells in recent studies including HCC cells. The aims of this study are to evaluate the antitumor effect of haprolid in HCC and to understand its underlying molecular mechanisms. Methods: The efficacy of haprolid was evaluated in human HCC cell lines (Huh-7, Hep3B and HepG2) and xenograft tumors (NMRI-Foxn1(nu) mice with injection of Hep3B cells). Cytotoxic activity of haprolid was determined by the WST-1 and crystal violet assay. Wound healing, transwell and tumorsphere assays were performed to investigate migration and invasion of HCC cells. Apoptosis and cell-cycle distribution were measured by flow cytometry. The effects of haprolid on the Rb/E2F and Akt/mTOR pathway were examined by immunoblotting and immunohistochemistry. Results: haprolid treatment significantly inhibited cell proliferation, migration and invasion in vitro. The epithelial–mesenchymal transition (EMT) was impaired by haprolid treatment and the expression level of N-cadherin, vimentin and Snail was downregulated. Moreover, growth of HCC cells in vitro was suppressed by inhibition of G1/S transition, and partially by induction of apoptosis. The drug induced downregulation of cell cycle regulatory proteins cyclin A, cyclin B and CDK2 and induced upregulation of p21 and p27. Further evidence showed that these effects of haprolid were associated with Rb/E2F downregulation and Akt/mTOR inhibition. Finally, in vivo nude mice experiments demonstrated significant inhibition of tumor growth upon haprolid treatment. Conclusion: Our results show that haprolid inhibits the growth of HCC through dual inhibition of Rb/E2F and Akt/mTOR pathways. Therefore, haprolid might be considered as a new and promising candidate for the palliative therapy of HCC. |
format | Online Article Text |
id | pubmed-7139901 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-71399012020-04-13 Haprolid Inhibits Tumor Growth of Hepatocellular Carcinoma through Rb/E2F and Akt/mTOR Inhibition Xing, Jun Bhuria, Vikas Bui, Khac Cuong Nguyen, Mai Ly Thi Hu, Zexi Hsieh, Chih-Jen Wittstein, Kathrin Stadler, Marc Wilkens, Ludwig Li, Jun Kalesse, Markus Bozko, Przemyslaw Plentz, Ruben R. Cancers (Basel) Article Background: Hepatocellular carcinoma (HCC) represents a major health burden with limited curative treatment options. There is a substantial unmet need to develop innovative approaches to impact the progression of advanced HCC. Haprolid is a novel natural component isolated from myxobacteria. Haprolid has been reported as a potent selective cytotoxin against a panel of tumor cells in recent studies including HCC cells. The aims of this study are to evaluate the antitumor effect of haprolid in HCC and to understand its underlying molecular mechanisms. Methods: The efficacy of haprolid was evaluated in human HCC cell lines (Huh-7, Hep3B and HepG2) and xenograft tumors (NMRI-Foxn1(nu) mice with injection of Hep3B cells). Cytotoxic activity of haprolid was determined by the WST-1 and crystal violet assay. Wound healing, transwell and tumorsphere assays were performed to investigate migration and invasion of HCC cells. Apoptosis and cell-cycle distribution were measured by flow cytometry. The effects of haprolid on the Rb/E2F and Akt/mTOR pathway were examined by immunoblotting and immunohistochemistry. Results: haprolid treatment significantly inhibited cell proliferation, migration and invasion in vitro. The epithelial–mesenchymal transition (EMT) was impaired by haprolid treatment and the expression level of N-cadherin, vimentin and Snail was downregulated. Moreover, growth of HCC cells in vitro was suppressed by inhibition of G1/S transition, and partially by induction of apoptosis. The drug induced downregulation of cell cycle regulatory proteins cyclin A, cyclin B and CDK2 and induced upregulation of p21 and p27. Further evidence showed that these effects of haprolid were associated with Rb/E2F downregulation and Akt/mTOR inhibition. Finally, in vivo nude mice experiments demonstrated significant inhibition of tumor growth upon haprolid treatment. Conclusion: Our results show that haprolid inhibits the growth of HCC through dual inhibition of Rb/E2F and Akt/mTOR pathways. Therefore, haprolid might be considered as a new and promising candidate for the palliative therapy of HCC. MDPI 2020-03-06 /pmc/articles/PMC7139901/ /pubmed/32155915 http://dx.doi.org/10.3390/cancers12030615 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Xing, Jun Bhuria, Vikas Bui, Khac Cuong Nguyen, Mai Ly Thi Hu, Zexi Hsieh, Chih-Jen Wittstein, Kathrin Stadler, Marc Wilkens, Ludwig Li, Jun Kalesse, Markus Bozko, Przemyslaw Plentz, Ruben R. Haprolid Inhibits Tumor Growth of Hepatocellular Carcinoma through Rb/E2F and Akt/mTOR Inhibition |
title | Haprolid Inhibits Tumor Growth of Hepatocellular Carcinoma through Rb/E2F and Akt/mTOR Inhibition |
title_full | Haprolid Inhibits Tumor Growth of Hepatocellular Carcinoma through Rb/E2F and Akt/mTOR Inhibition |
title_fullStr | Haprolid Inhibits Tumor Growth of Hepatocellular Carcinoma through Rb/E2F and Akt/mTOR Inhibition |
title_full_unstemmed | Haprolid Inhibits Tumor Growth of Hepatocellular Carcinoma through Rb/E2F and Akt/mTOR Inhibition |
title_short | Haprolid Inhibits Tumor Growth of Hepatocellular Carcinoma through Rb/E2F and Akt/mTOR Inhibition |
title_sort | haprolid inhibits tumor growth of hepatocellular carcinoma through rb/e2f and akt/mtor inhibition |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139901/ https://www.ncbi.nlm.nih.gov/pubmed/32155915 http://dx.doi.org/10.3390/cancers12030615 |
work_keys_str_mv | AT xingjun haprolidinhibitstumorgrowthofhepatocellularcarcinomathroughrbe2fandaktmtorinhibition AT bhuriavikas haprolidinhibitstumorgrowthofhepatocellularcarcinomathroughrbe2fandaktmtorinhibition AT buikhaccuong haprolidinhibitstumorgrowthofhepatocellularcarcinomathroughrbe2fandaktmtorinhibition AT nguyenmailythi haprolidinhibitstumorgrowthofhepatocellularcarcinomathroughrbe2fandaktmtorinhibition AT huzexi haprolidinhibitstumorgrowthofhepatocellularcarcinomathroughrbe2fandaktmtorinhibition AT hsiehchihjen haprolidinhibitstumorgrowthofhepatocellularcarcinomathroughrbe2fandaktmtorinhibition AT wittsteinkathrin haprolidinhibitstumorgrowthofhepatocellularcarcinomathroughrbe2fandaktmtorinhibition AT stadlermarc haprolidinhibitstumorgrowthofhepatocellularcarcinomathroughrbe2fandaktmtorinhibition AT wilkensludwig haprolidinhibitstumorgrowthofhepatocellularcarcinomathroughrbe2fandaktmtorinhibition AT lijun haprolidinhibitstumorgrowthofhepatocellularcarcinomathroughrbe2fandaktmtorinhibition AT kalessemarkus haprolidinhibitstumorgrowthofhepatocellularcarcinomathroughrbe2fandaktmtorinhibition AT bozkoprzemyslaw haprolidinhibitstumorgrowthofhepatocellularcarcinomathroughrbe2fandaktmtorinhibition AT plentzrubenr haprolidinhibitstumorgrowthofhepatocellularcarcinomathroughrbe2fandaktmtorinhibition |